Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02746991
Other study ID # PSV-FAI-005
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2, 2015
Est. completion date October 4, 2019

Study information

Verified date July 2020
Source EyePoint
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye. Patients will be randomized to receive either a sham injection or the FAI insert and will be observed for three years following treatment.


Description:

This is a phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye. Patients will be randomized to receive either a sham injection or the FAI insert and will be observed for three years following treatment.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date October 4, 2019
Est. primary completion date October 4, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or non pregnant female at least 18 years of age at time of consent

- One or both eyes having a history of recurrent non-infectious uveitis affecting the posterior segment of the eye with or without anterior uveitis > 1 year duration

- At the time of enrollment (Day 1), study eye has < 10 anterior chamber cells/High Power Field (HPF) and a vitreous haze = grade 2.

- Visual acuity of study eye is at least 15 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart

- Subject is not planning to undergo elective ocular surgery during the study

- Subject has ability to understand and sign the Informed Consent Form

- Subject is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

- During the 12 months prior to enrollment (Day 1), the study eye has either received treatment:

- systemic corticosteroid or other systemic therapies given for at least 3 months, and/or

- at least 2 intra- or peri-ocular administrations of corticosteroid for management of uveitis

OR the study eye has experienced recurrence:

• at least 2 separate recurrences of uveitis requiring systemic, intra- or peri-ocular injection of corticosteroid

Exclusion Criteria:

- Allergy to fluocinolone acetonide or any component of the Fluocinolone Acetonide Intravitreal (FAI) insert

- History of posterior uveitis only that is not accompanied by vitritis or macular edema

- History of iritis only and no vitreous cells, anterior chamber cells or vitreous haze

- Uveitis with infectious etiology

- Vitreous hemorrhage

- Intraocular inflammation associated with a condition other than noninfectious uveitis (e.g. intraocular lymphoma)

- Ocular malignancy in either eye, including choroidal melanoma

- Toxoplasmosis scar in study eye or scar related to previous viral retinitis

- Previous viral retinitis

- Current viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, mycobacterial infections of the eye or fungal diseases of ocular structures

- Media opacity precluding evaluation of retina and vitreous

- Peripheral retinal detachment in area of insertion

- Diagnosis of any form of glaucoma or ocular hypertension in study eye at Screening, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable Intraocular pressure (IOP) in the normal range (10-21 mmHg)

- IOP > 21 mmHg or concurrent therapy at Screening with any IOP-lowering pharmacologic agent in the study eye

- Chronic hypotony (< 6 mmHg)

- Ocular surgery on the study eye within 3 months prior to study Day 1

- Capsulotomy in study eye within 30 days prior to study Day 1

- Prior intravitreal treatment of study eye with Retisert within 36 months prior to study Day 1

- Prior intravitreal treatment of study eye with Ozurdex within 6 months prior to study Day 1

- Prior intravitreal treatment of study eye with Triesence or Trivaris within 3 months prior to study Day 1

- Prior peri-ocular or subtenon steroid treatment of study eye within 3 months prior to study Day 1

- Subjects requiring chronic systemic or inhaled corticosteroid therapy (>15mg prednisone daily) or chronic systemic immunosuppressive therapy

- Excluding certain skin cancers (specifically, basal cell carcinoma and squamous cell carcinoma), any malignancy receiving treatment, or in remission less than 5 years prior to study Day 1

- Subjects who have tested positive for human immune deficiency virus (HIV), tuberculosis or syphilis

- Systemic infection within 30 days prior to study Day 1

- Any severe acute or chronic medical or psychiatric condition that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, could make the subject inappropriate for entry into this study

- Any other systemic or ocular condition which, in the judgment of the investigator, could make the subject inappropriate for entry into this study

- Treatment with an investigational drug or device within 30 days prior to study Day 1

- Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to study Day 1 until the Month 12 Visit

- Subjects unlikely to comply with the study protocol or who are likely to be lost to follow-up within three years

Study Design


Intervention

Drug:
Sham Injection
Placebo
FAI Insert
Fluocinolone Acetonide

Locations

Country Name City State
India C.H. Nagri Municipal Eye Hospital Ahmedabad Gujarat
India Sankara Nethralaya hospital Chennai Tamil Nadu
India Sri Ramachandra Hospital Chennai Tamil Nadu
India Vasan Eye Care Hospital Chennai Tamil Nadu
India Dr. Shroff's Charity Eye Hospital Daryaganj New Delhi
India Sri Sankaradeva Nethralaya, Guwahati Guwahati Assam
India LV. Prasad Eye Institute Hyderabad Andhra Pradesh
India J L Rohatgi Memorial Eye Hospital Kanpur Uttar Pradesh
India Regional Institute of Ophthalmology Kolkata West Bengal
India King George's Medical University Lucknow Uttar Pradesh
India Seth G.S. Medical College & K.E.M Hospital Mumbai Maharashtra
India ICARE Eye Hospital and Research centre Noida Uttar Pradesh
India Regional Institute of Opthalmology Patna Bihar
India Deenanath Mangeshkar Hospital, Pune Pune Maharashtra
India PBMA'S, H. V. Desai Eye Hospital Pune Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
EyePoint

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months Proportion of Subjects with Recurrence of Uveitis in the Study Eye within 6 Months Including Reason for Imputed Recurrence (ITT Population) 6 Months
Secondary Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months Proportion of Subjects with Recurrence of Uveitis in the Study Eye at 36 Months Including Reason for Imputed Recurrence (ITT Population) 36 Months
See also
  Status Clinical Trial Phase
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Phase 4
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Recruiting NCT05101928 - Ozurdex Monotherapy Trial Phase 4
Completed NCT00167583 - Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB) Phase 3
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT00407316 - Quality of Life and Visual Function in Uveitis Patients Phase 0
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Completed NCT02725177 - Ocular Sarcoidosis Open Label Trial of ACTHAR Gel N/A
Completed NCT00908466 - Sirolimus as Therapeutic Approach to Uveitis Phase 1
Completed NCT00615693 - Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Phase 2
Completed NCT00404612 - A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Phase 3
Completed NCT00404742 - A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Phase 3
Completed NCT00404885 - A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis Phase 3
Completed NCT01789320 - Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Phase 1/Phase 2
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Completed NCT00407056 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis Phase 3
Completed NCT00406887 - Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis Phase 3
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3